Neovasc taps former Boston Scientific CRM vet Colen for CEO | Personnel Moves January 22, 2018

Neovasc (NSDQ:NVCN) said today it tapped former Boston Scientific (NYSE:BSX) cardiac rhythm management lead Fred Colen as its new chief executive officer, with former CEO Alexei Marko staying on as an advisor and member of the company’s board of directors. The move comes as part of a company-wide strategy looking to support commercialization efforts for its Reducer product in Europe and the progression of its Tiara mitral valve replacement device’s clinical program, the Vancouver, Canada-based company said. “After ten years building Neovasc, I am convinced that now is the time for new leadership to take the company to the next level. I am especially pleased that an industry leader of Fred Colen’s caliber has accepted this opportunity. I look forward to my continued involvement as a board member,” Marko said in prepared remarks. “Neovasc has reached an important turning point, and, as such, we have conducted a search for a leader with the experience and skill set to build on the progress made by Alexei Marko during his tenure as CEO. Fred Colen is a seasoned medical device executive with an outstanding track record and reputation as a strong leader.  We believe he is exceptionally well qualified to lead Neovasc in its next phase of growth. Alexei Marko has been a very capable leader since the company’s inception ten years ago. His considerable expertise, determination, and focus have been instrumental in executing Neovasc’s c...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Bayer biogennix Boston Scientific Bristol-Myers Squibb Co. Cardinal Health Dentsply Sirona gilupi imaginmedical Medtronic Neovasc Inc. Spinal Elements Source Type: news